摘要
Drug-induced liver injury(DILI)is a rare but potentially life-threatening condition,which accounts for the majority of acute liver failure cases in the US and EU.Unlike direct hepatoxicity,which is mainly caused by acetaminophen,idiosyncratic DILI is unpredictable and occurs unrelated to the dose or frequency of the medication.Interestingly,DILI cannot only be caused by a large variety of prescription drugs,but also by herbal and dietary supplements(HDS).While HDS-DILI has already played a role in Asian countries like China or Korea for a long time,there is also an increasing incidence of HDS-DILI in countries with formerly less HDS-DILI cases such as the US,presumably due to a rising usage of those remedies(1).
基金
supported by TransBioLine[Translational Safety Biomarker Pipeline(TransBioLine):Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
grant agreement ID:821283
S.W.and A.L.G.].The TransBioLine project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No.821283.
